Join to access to all OVN content. Join for Free
The MSL Execution Factor (Book Review)
Medical Science Liaisons Execution Factor MSL success building relationships resilience in MSL roles

The MSL Execution Factor (Book Review)


Share This Article


Summary

In this episode, Jihad “JR” Rizkallah joins Tom Caravela to delve into the core elements of success for Medical Science Liaisons through the lens of "The Execution Factor." JR emphasizes the significance of vision, passion, and resilience in MSL roles and highlights action as the central hub for effectiveness. The conversation explores overcoming challenges, building robust relationships, and utilizing LinkedIn for meaningful connections. JR also discusses the importance of encouragement, recognition, and the ethos of paying it forward within the MSL community. The episode provides valuable insights for MSLs aiming to enhance their impact and effectiveness in the field.

My guest today is Jihad “JR” Rizkallah, Director, MSLs at Sunovion. JR discusses MSL Execution Factors based on the book by Kim Perell.

JR Shares…

👉 Why he felt compelled to do this specific book review and discussion for the MSL community
👉 What the key factors of Execution are
👉 Why vision and action are so key in your success
👉 Why and how to use relationships to excel in your career as an MSL
👉 How to be resilient and overcome challenges

Click for Source
Medical Science Liaisons, Execution Factor, MSL success, building relationships, resilience in MSL roles

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN